{
  "trial_id": "NCT01080391",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, race, ECOG performance status, prior treatment regimens, serum M-protein levels, urine Bence-Jones protein levels, serum quantitative immunoglobulin (qIgA) levels, absolute neutrophil count, hemoglobin levels, platelet count, creatinine clearance, hepatic function (serum ALT and direct bilirubin levels), life expectancy, presence of significant neuropathy, history of myocardial infarction, presence of uncontrolled hypertension or diabetes, history of other malignancies, presence of active infections (HIV, hepatitis B or C), history of allergy to Captisol, presence of pleural effusions or ascites, and history of graft-vs-host disease.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race/Ethnicity",
          "race"
        ],
        [
          "Prior Bortezomib Exposure",
          "prior treatment regimens"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Serum \u03b22 Microglobulin",
        "Prior Lenalidomide Exposure"
      ],
      "remaining_candidate_features": [
        "ECOG performance status",
        "serum M-protein levels",
        "urine Bence-Jones protein levels",
        "serum quantitative immunoglobulin (qIgA) levels",
        "absolute neutrophil count",
        "hemoglobin levels",
        "platelet count",
        "creatinine clearance",
        "hepatic function (serum ALT and direct bilirubin levels)",
        "life expectancy",
        "presence of significant neuropathy",
        "history of myocardial infarction",
        "presence of uncontrolled hypertension or diabetes",
        "history of other malignancies",
        "presence of active infections (HIV, hepatitis B or C)",
        "history of allergy to Captisol",
        "presence of pleural effusions or ascites",
        "history of graft-vs-host disease"
      ]
    },
    "processed-gen-response": "Age, sex, race, ECOG performance status, prior treatment regimens, serum M-protein levels, urine Bence-Jones protein levels, serum quantitative immunoglobulin (qIgA) levels, absolute neutrophil count, hemoglobin levels, platelet count, creatinine clearance, hepatic function (serum ALT and direct bilirubin levels), life expectancy, presence of significant neuropathy, history of myocardial infarction, presence of uncontrolled hypertension or diabetes, history of other malignancies, presence of active infections (HIV, hepatitis B or C), history of allergy to Captisol, presence of pleural effusions or ascites, and history of graft-vs-host disease."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG performance status, Serum M-protein, Urine Bence-Jones protein, Serum quantitative immunoglobulin (qIgA), Number of prior treatment regimens, Hemoglobin, Platelet count, Creatinine clearance (CrCl), Absolute neutrophil count, Serum alanine aminotransferase (ALT), Serum direct bilirubin, ",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ],
        [
          "Prior Bortezomib Exposure",
          "Number of prior treatment regimens"
        ],
        [
          "Serum \u03b22 Microglobulin",
          "Serum M-protein"
        ]
      ],
      "remaining_reference_features": [
        "Prior Lenalidomide Exposure"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "ECOG performance status",
        "Urine Bence-Jones protein",
        "Serum quantitative immunoglobulin (qIgA)",
        "Hemoglobin",
        "Platelet count",
        "Creatinine clearance (CrCl)",
        "Absolute neutrophil count",
        "Serum alanine aminotransferase (ALT)",
        "Serum direct bilirubin"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, ECOG performance status, Serum M-protein, Urine Bence-Jones protein, Serum quantitative immunoglobulin (qIgA), Number of prior treatment regimens, Hemoglobin, Platelet count, Creatinine clearance (CrCl), Absolute neutrophil count, Serum alanine aminotransferase (ALT), Serum direct bilirubin"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, Hemoglobin, Absolute Neutrophil Count, Platelet Count, Creatinine Clearance, Serum M-protein, Urine Bence-Jones Protein, Serum Quantitative Immunoglobulin, Prior Treatment Regimens, Prior Response to Treatment, Time Since Diagnosis, Time Since Last Treatment.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ],
        [
          "Prior Bortezomib Exposure",
          "Prior Treatment Regimens"
        ],
        [
          "Prior Lenalidomide Exposure",
          "Prior Treatment Regimens"
        ]
      ],
      "remaining_reference_features": [
        "Serum \u03b22 Microglobulin"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "ECOG Performance Status",
        "Hemoglobin",
        "Absolute Neutrophil Count",
        "Platelet Count",
        "Creatinine Clearance",
        "Serum M-protein",
        "Urine Bence-Jones Protein",
        "Serum Quantitative Immunoglobulin",
        "Prior Response to Treatment",
        "Time Since Diagnosis",
        "Time Since Last Treatment"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, ECOG Performance Status, Hemoglobin, Absolute Neutrophil Count, Platelet Count, Creatinine Clearance, Serum M-protein, Urine Bence-Jones Protein, Serum Quantitative Immunoglobulin, Prior Treatment Regimens, Prior Response to Treatment, Time Since Diagnosis, Time Since Last Treatment."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ECOG performance status, number of prior regimens, time since diagnosis, prior therapies, serum M-protein, urine Bence-Jones protein, serum quantitative immunoglobulin, hemoglobin, absolute neutrophil count, platelet count, creatinine clearance, liver function tests (ALT, bilirubin).",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race/Ethnicity",
          "race"
        ],
        [
          "Prior Bortezomib Exposure",
          "prior therapies"
        ],
        [
          "Prior Lenalidomide Exposure",
          "prior therapies"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Serum \u03b22 Microglobulin"
      ],
      "remaining_candidate_features": [
        "ECOG performance status",
        "number of prior regimens",
        "time since diagnosis",
        "serum M-protein",
        "urine Bence-Jones protein",
        "serum quantitative immunoglobulin",
        "hemoglobin",
        "absolute neutrophil count",
        "platelet count",
        "creatinine clearance",
        "liver function tests (ALT, bilirubin)"
      ]
    },
    "processed-gen-response": "Age, sex, race, ECOG performance status, number of prior regimens, time since diagnosis, prior therapies, serum M-protein, urine Bence-Jones protein, serum quantitative immunoglobulin, hemoglobin, absolute neutrophil count, platelet count, creatinine clearance, liver function tests (ALT, bilirubin)."
  }
}